Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.49 |
| ▸ | NPY4R | P50391 | 5/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.48 |
| ▸ | NPY1R | P25929 | 4/20 | 0.48 |
| ▸ | NPY2R | P49146 | 2/20 | 0.48 |
| ▸ | NMT1 | P30419 | 5/20 | 0.47 |
| ▸ | NMT2 | O60551 | 4/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15185938 | 0.94 | NPY4R (0.51) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL16359252 | 0.91 | NPY4R (0.52) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL19696599 | 0.90 | TLR2 (0.55) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL12749418 | 0.86 | TLR2 (0.68) | TLR2ROCK2PRKACAAKT3NMT1 | |
| SCHEMBL12971402 | 0.86 | SLC6A5 (0.53) | NPY4RNPY5RNPY1RNPY2RNMT1 | |
| SCHEMBL12971400 | 0.86 | SLC6A5 (0.53) | NPY4RNPY5RNPY1RNPY2RNMT1 | |
| SCHEMBL7754998 | 0.86 | TLR2 (0.68) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL22850479 | 0.86 | NPY4R (0.43) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL14583963 | 0.86 | TLR2 (0.67) | TLR2ROCK2PRKACAAKT3NPY4R | |
| SCHEMBL13363677 | 0.85 | SLC6A5 (0.56) | TLR2ROCK2PRKACAAKT3NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023028338-A2 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023009554-A1 | METHODS TO REDUCE ADVERSE EFFECTS OF GENE OR BIOLOGICS THERAPY | AVILAR THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2022235699-A2 | POTENT ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |